Observational Study on the Incidence of NSF in Renal Impaired Patients Following DOTAREM Administration (NSsaFe)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
Child, Adult, Older Adult
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with moderate to severe and end stage renal impairment or dialysis
Patients scheduled for a contrast enhanced MRI with DOTAREM
Patients with moderate to severe and end stage renal impairment or dialysis, scheduled for a contrast enhanced MRI with DOTAREM
Patient who has received a Gadolinium Based Contrast Agent within the past 12 months prior to inclusion in this study except if the GBCA received is Dotarem